Benzbromarone
Chemical compound / From Wikipedia, the free encyclopedia
Benzbromarone is a uricosuric agent and non-competitive inhibitor of xanthine oxidase[1] used in the treatment of gout, especially when allopurinol, a first-line treatment, fails or produces intolerable adverse effects. It is structurally related to the antiarrhythmic amiodarone.[2]
Quick Facts Clinical data, AHFS/Drugs.com ...
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.020.573 |
Chemical and physical data | |
Formula | C17H12Br2O3 |
Molar mass | 424.088 g·mol−1 |
3D model (JSmol) | |
Melting point | 161 to 163 °C (322 to 325 °F) |
| |
| |
NY (what is this?) (verify) |
Close
Benzbromarone is highly effective and well tolerated,[3][4][5][6] and clinical trials as early as 1981 and as recently as April 2008 have suggested it is superior to both allopurinol, a non-uricosuric xanthine oxidase inhibitor, and probenecid, another uricosuric drug.[7][8]